Intellia Therapeutics Stock Forecast, Price & News

+3.41 (+2.27 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume701,876 shs
Average Volume1.71 million shs
Market Capitalization$11.31 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Intellia Therapeutics logo

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.92 out of 5 stars

Medical Sector

646th out of 1,352 stocks

Diagnostic Substances Industry

9th out of 25 stocks

Analyst Opinion: 2.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

Is Intellia Therapeutics a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Intellia Therapeutics?

Wall Street analysts have given Intellia Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intellia Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Intellia Therapeutics

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its earnings results on Thursday, August, 5th. The company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.40. The company had revenue of $6.55 million for the quarter, compared to analyst estimates of $12.21 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 39.01% and a negative net margin of 442.58%. The company's quarterly revenue was down 59.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.61) EPS.
View Intellia Therapeutics' earnings history

How has Intellia Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NTLA shares have increased by 1,109.5% and is now trading at $153.85.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NTLA?

17 brokerages have issued twelve-month price objectives for Intellia Therapeutics' stock. Their forecasts range from $52.00 to $252.00. On average, they expect Intellia Therapeutics' share price to reach $143.38 in the next twelve months. This suggests that the stock has a possible downside of 6.8%.
View analysts' price targets for Intellia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the following people:
  • John M. Leonard, President, Chief Executive Officer & Director
  • Glenn Goddard, Executive VP, Chief Financial & Accounting Officer (LinkedIn Profile)
  • Laura Sepp-Lorenzino, Chief Scientific Officer & Executive VP
  • David Lebwohl, Chief Medical Officer & Executive Vice President
  • Eliana Clark, Senior Vice President-Technical Operations

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

Who are some of Intellia Therapeutics' key competitors?

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.28%), Vanguard Group Inc. (8.20%), BlackRock Inc. (7.29%), Sumitomo Mitsui Trust Holdings Inc. (4.59%), Nikko Asset Management Americas Inc. (4.49%) and FMR LLC (3.71%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John M Leonard, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics

Which major investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Alliancebernstein L.P., Invesco Ltd., BlackRock Inc., Compagnie Lombard Odier SCmA, and Integral Health Asset Management LLC. Company insiders that have sold Intellia Therapeutics company stock in the last year include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John M Leonard, Jose E Rivera, Laura Sepp-Lorenzino, and Perry A Karsen.
View insider buying and selling activity for Intellia Therapeutics
or view top insider-selling stocks.

Which major investors are buying Intellia Therapeutics stock?

NTLA stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Jefferies Group LLC, Discovery Value Fund, Vanguard Group Inc., Franklin Resources Inc., Victory Capital Management Inc., Himension Fund, and Eagle Asset Management Inc..
View insider buying and selling activity for Intellia Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $153.85.

How much money does Intellia Therapeutics make?

Intellia Therapeutics has a market capitalization of $11.31 billion and generates $57.99 million in revenue each year. The company earns $-134,230,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

Intellia Therapeutics employs 312 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is

Where are Intellia Therapeutics' headquarters?

Intellia Therapeutics is headquartered at 40 Erie Street Suite 130, Cambridge MA, 02139.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at (857) 285-6200 or via email at [email protected]

This page was last updated on 9/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.